Cadrofloxacin (Caderofloxacin; CS-940), a orally active fluoroquinolone, is effective against aerobic/anaerobic Gram-positive and Gram-negative bacteria. Cadrofloxacin can be used for the research of infectious diseases[1][2][3].
Cadrofloxacin against M.tuberculosis with a MIC50 of 0.25 μg/mL[1].Cadrofloxacin against Acinetobacter spp. and Stenotrophomonas (Xanthomonas) maltophilia with MIC90s of 0.03 and 2 μg/ml, respectively[2].Cadrofloxacin against Haemophilus influenzae, Moraxella catarrhalis, and Neisseria spp. with MIC90s less than or equal to 0.06 μg/mL[2].Cadrofloxacin against members of the family Enterobacteriaceae with MIC90s of 0.015 to 16 μg/mL (median MIC90, 0.06 μg/mL)[2].
Cadrofloxacin (9 mg/kg; i.g.; once or twice daily for 14 consecutive days) increases the activity of hepatic CYP2E1 in rats[2].
[1]. Bryskier A, et al. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs. 2002 Feb;11(2):233-58.
[2]. Biedenbach DJ, et al. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30.
[3]. Bryskier A, et al. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs. 2002 Feb;11(2):233-58.